Printer Friendly

CYGNUS ANNOUNCES NEW SCIENTIFIC AFFAIRS VP FORMERLY WITH CHIRON, BEECHAM, SYNTEX IN SENIOR REGULATORY POSITIONS

 CYGNUS ANNOUNCES NEW SCIENTIFIC AFFAIRS VP FORMERLY WITH CHIRON, BEECHAM, SYNTEX IN SENIOR REGULATORY POSITIONS
 REDWOOD CITY, Calif., May 12 /PRNewswire/ -- Cygnus Therapeutic Systems (NASDAQ: CYGN), a company focused on transdermal drug delivery, today announced the appointment of Alan F. Russell, Ph.D., to the newly created position of vice president of scientific affairs. Russell will be responsible for regulatory affairs, medical/clinical affairs, project management, quality control and quality assurance.
 "Cygnus is at the stage where we need Alan's experience and expertise in managing all the elements of new product development to ensure expeditious regulatory review," according to Dr. Gregory B. Lawless, president and chief executive officer.
 Russell was vice president for scientific affairs at Chiron Corp. for the last five years, and previously held the same positions during his 10 years at Syntex, including director of regulatory affairs for investigational drugs.
 "This is an exciting time for me to be joining the Cygnus team," Russell said. "The Cygnus product pipeline is full with excellent pharmaceutical products, and I am truly looking forward to working with the project teams to assure timely FDA approvals."
 Russell earned his Ph.D. in organic chemistry from the University of South Wales in Australia. He earned a B.S. with honors in chemistry at Exeter University in England. He was a Senior Dernham Fellow in Oncology of the American Cancer Society at Stanford University School of Medicine, where he was involved in investigations of DNA replication under the supervision of Dr. Arthur Kornberg, Nobel Laureate. Russell also holds M.B.A. and J.D. degrees from the University of Santa Clara, and is a member of the California Bar.
 Cygnus is a leader in the development of advanced transdermal drug delivery systems. Cygnus nicotine transdermal product, Nicotrol(TM) was approved by the FDA in April and will be marketed in the United States by Parke-Davis, a division of Warner-Lambert Co. The company has two other products in advanced clinical trials, an estradiol patch for the treatment of the symptoms of menopause and the prevention of osteoporosis; and a fentanyl patch for moderate to severe post-operative pain management. Cygnus Therapeutic Systems has 11 U.S. patents issued or allowed and over 300 patent applications worldwide covering its transdermal technology.
 -0- 5/12/92
 /CONTACT: Shirley Clayton of Cygnus, 415-369-4300/
 (CYGN) CO: Cygnus Therapeutic Systems ST: California IN: MTC SU: PER


MC-RM -- SF004 -- 9234 05/12/92 15:02 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 12, 1992
Words:405
Previous Article:AFL-CIO: A REALITY CHECK ON BALANCED BUDGET AMENDMENT
Next Article:BRONX CEREMONY TO HIGHLIGHT NEW YORK'S U.S. OLYMPIC SPIRIT WEEK
Topics:


Related Articles
CYGNUS NAMES NEW PRESIDENT AND CEO FORMER CHIRON PRESIDENT JOINS TO LEAD COMMERCIALIZATION
CELL GENESYS ANNOUNCES KEY PRODUCT DEVELOPMENT HIRES
APPOINTMENT OF TWO VICE PRESIDENTS COMPLETES CYGNUS SENIOR MANAGEMENT TEAM
SYNTEX AND CHIRON ANNOUNCE NEW RESEARCH AND DEVELOPMENT COLLABORATION
DR. NEIL ACKERMAN JOINS CYGNUS AS VICE PRESIDENT OF RESEARCH AND DEVELOPMENT
CYGNUS PROMOTES TWO OFFICERS; ROGER FRANCIS AND ALAN RUSSELL NAMED SENIOR VICE PRESIDENTS
CELL GENESYS ANNOUNCES EXECUTIVE PROMOTIONS
Alan F. Russell, Ph.D. Named President and CEO of AvMax, Inc.
Chiron Names Peder K. Jensen Corporate Vice President and Head of Development.
Chiron Names Howard Pien Chief Executive Officer; New CEO Brings Depth of Global Management Experience to New Position - Sean Lance to Continue as...

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters